Navigation Links
First Cancer Diagnostic Test Based on Rosetta Genomics' Proprietary MicroRNA Technology Receives Regulatory Approval
Date:7/22/2008

owed that 40 percent of samples diagnosed as squamous-cell lung cancer at regional labs were later reclassified as other lung cancers at central labs.

Rosetta Genomics expects two additional tests based on its microRNA technology to be validated and submitted for regulatory approval during the second half of 2008 by laboratories in the United States. One test is designed to differentiate mesothelioma, an asbestos-associated cancer that develops in the pleura, from adenocarcinomas that either arise in the lung or spread to the lung and pleura from other sites. Another test is designed to identify the origin of a metastasis in patients presenting with cancer of unknown primary (CUP).

About microRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic strategy for many diseases.

About Rosetta Genomics

Rosetta Genomics (Nasdaq: ROSG) is a leader in the field of microRNA. Founded in 2000, the company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of the
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Ekkyo Describes the First Benefits of Controlled Hyperthermia in Humans in "Lasers in Surgery and Medicine"
2. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
3. Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimers Drug After Flurizans Discontinuation
4. Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
5. Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments
6. Patient Receives vProtect(TM) Luminal Shield in First-Ever Vulnerable Plaque Clinical Trial
7. Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
8. First Breast Cancer Patient Receives Treatment in National Electronic Brachytherapy Registry Launched by Three Physician Societies
9. Olanzapine Long-Acting Injection (LAI) Data Presented at First Annual Schizophrenia International Research Society Conference
10. Accumetrics Announces the Launch and First Patient Enrolled Into the GRAVITAS Trial
11. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2008)... A study published in the,scientific journal Natur...rted that InVitria,s ( http://www.InVitria.com ) C...effective replacement to bovine serum albumin,in E...d state of embryonic stem cell,self-renewal," disc...nant,albumin in place of animal-derived serum to e...
(Date:10/7/2008)...ligen Therapeutics Inc.,today announced that in vi...dates were presented at the XXII International Com...ighlighted the candidates, efficacy in,several ani...se highlighted presentations, as well as several i...l the deep expertise and expanding,knowledge base ...
(Date:10/7/2008)...g-term benefits and value in,moderate to severe Cr...ge,of Gastroenterology (ACG), ORLANDO, Fla. Oct. ...presented this week by UCB at the American College...ate that CIMZIA(R) (certolizumab pegol) - the,only...lpha) - provides,sustained improvement in symptoms...
(Date:10/7/2008)... Ardea Biosciences, Inc.,(Nasdaq: RDEA ) announce...and Highly Selective MEK1/2 Inhibitor is Beneficia...ic Colitis in Mice," was presented at the,American...ting in Orlando,Florida. The poster, which provid...ompany,s lead mitogen-activated ERK kinase (MEK) i...
Breaking Medicine Technology:In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 2In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 3In Vivo Data on Taligen Therapeutics' Pipeline Candidates Presented at the XXII International Complement Workshop 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 2CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 3CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 4CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 5CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 6CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 7CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 8CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients 9Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 2Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 3Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting 4Philadelphia Insurance Companies Launches Home Health Care and Hospice Products 20892 1Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 1Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 2Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 3Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 4Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 5Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 6Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 7Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients 2294 8Breast Feeding More Protective for Girls Than Boys 20888 1Breast Feeding More Protective for Girls Than Boys 20888 2Boca Pharmacal Receives FDA Approval for Carbinoxamine Maleate 4 mg Tablet 20882 1
(Date:10/7/2008)...han 4,300 Activity Bags Donated to Area Youth in H...nio, HOUSTON, Oct. 7 /PRNewswire/ -- Carlson Hote...ether to provide more than 1,900 activity bags,to ... area. The tote bags,contained a fun activity book...., (Photo: http://www.newscom.com/cgi-bin/prnh/2...
(Date:10/7/2008)...N, N.J., Oct. 7 /PRNewswire-FirstCall/ -- Majesco ...ive provider of video games for the mass,market, t...matum 2009 has,gone gold and is scheduled to ship ... of its kind to integrate a celebrity fitness trai... life coach on the popular television,series "The ...
(Date:10/7/2008)...Y, France, October 7 /PRNewswire-FirstCall/ -- Sta...red into an exclusive agreement with,Catalent for ...line,autoinjector, ADREFLEX(R), co-developed and c...LC., ADREFLEX(R) consists of a syringe pre-filled...t and paediatric use (0.3 and 0.15 mg), in an,auto...
(Date:10/7/2008)...LAND, Oct. 7 /PRNewswire/ -- Cleveland Medical Dev... $1.23 million in NIH SBIR,FastTrack funding from ...une(TM), a system to augment stimulator programmin...arkinson,s disease (PD). CleveMed is,collaborating...storation of,the Cleveland Clinic Foundation, a wo...
Breaking Medicine News(10 mins):Health News:Carlson Hotels Worldwide Partners With the American Red Cross in Texas to Provide Relief for Children Affected by Hurricane Ike 2Health News:Majesco Entertainment and Interactive Game Group Announce 'Jillian Michaels' Fitness Ultimatum 2009' Ships to Stores October 21st 2Health News:Majesco Entertainment and Interactive Game Group Announce 'Jillian Michaels' Fitness Ultimatum 2009' Ships to Stores October 21st 3Health News:Stallergenes Partners With Catalent and the Medical House for Commercialization of Adrenaline Autoinjector in Europe 2Health News:CleveMed Receives $1.23 Million in NIH Funding to Develop a System to Augment Deep Brain Stimulation Programming in Parkinson's Disease 2
...er of the Bernhard Nocht Institute for Tropical Me...arial //parasite avoids the immune system by killi...s known that after infecting man, malarial parasit...ct the red blood cells, but it was not known how t...
...sity, University of California-Davis and Justus-Li...treatments //could be possible for autism and Park...focused their attention despite being distracted u...t a measure of cognitive deficit in mice that is r...
... are born infected with human cytomegalovirus, or ...anent disabilities due to the virus – almost one a...oss, vision loss, mental disability, a lack of coo... for Disease Control and Prevention, CMV is as com...
...from infection causing agents. Regulatory T-cells,...s of life itself to recognize// the invaders and d...ese cells seem to protect certain bacteria, viruse...ical college of Georgia, studied the T-cells in th...
Other Medicine News:Health News:Scientist Study New Treatment Modality for Psychiatric Disorders Using Mice 2Health News:Scientist Study New Treatment Modality for Psychiatric Disorders Using Mice 3Health News:Innovative Method for Creating a Human Cytomegalovirus Vaccine Outlined 2Health News:Regulatory T-cells – Protector or Cause of Diseases 2Health News:Regulatory T-cells – Protector or Cause of Diseases 3
1 x 2 teeth, cross serrated 5 mm 60 degree angled platform. Round knurled handle with polished finish.
Narrow 4 mm long smooth platform. Serrated handle with polished finish.
1 mm smooth 45 degrees angled jaws. Cross action serrated handle with polished finish.
Oval solid 16 mm wide lower plate. Open upper plate with inside dimensions 12 mm x 14 mm. Serrated handle with locking thumb screw and polished finish.
Medicine Products: